OXS C3550

Drug Profile

OXS C3550

Alternative Names: Anti-CD16-IL-15-anti-CD33 TriKE; OXS-C3550; OXS-C3550 TriKE

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Minnesota
  • Developer GT Biopharma; University of Minnesota
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD33 antigen modulators; IgG receptor modulators; Interleukin 15 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 29 Jan 2018 GT Biopharma plans the IND-enabling studies mid-2018 (GT Biopharma Pipeline)
  • 24 Jan 2018 GT Biopharma plans an FDA clinical trial in Acute myeloid leukaemia in the second half of 2018
  • 13 Dec 2017 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia released by GT Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top